PTC Therapeutics Inc (STU:BH3)
€ 36.8 0 (0%) Market Cap: 2.89 Bil Enterprise Value: 2.25 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

PTC Therapeutics Inc to Host PTC518 Huntington Disease Deep Dive Webinar Transcript

Apr 15, 2021 / 01:00PM GMT
Release Date Price: €40
Operator

Good day, and thank you for standing by. Welcome to the PTC Huntington's Disease Deep Dive Conference Call. (Operator Instructions). Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your host today, Kylie O'Keefe, Senior Vice President, Commercial and Corporate Strategy. Please go ahead.

Kylie O;Keefe
PTC Therapeutics, Inc. - VP, Head of Global Strategic Marketing & Business Intelligence

' -

Good morning, everyone. Thank you for joining us today for the first addition to our 2021 deep dive series. Today, we will be focused on our PTC518 program in Huntington's disease.

Joining me on today's call is our Chief Executive Officer, Dr. Stuart Peltz; our Chief Development Officer, Dr. Matthew Klein; and our Executive Director of Biology, Dr. Anu Bhattacharyya. Slides are available on the Investors section of the website for you to follow along during the presentation today.

I will now pass the call over to our Chief Executive Officer, Stuart Peltz. Stu?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot